Shots:
- BMS has reported the topline P-III (ALOFT-IPF) trial data assessing admilparant (60 & 120mg, PO, BID) vs PBO for ≥52wks. in adults (n=~1,255; ≥40yrs.) with idiopathic pulmonary fibrosis (IPF)
- Trial met its 1EP at 60mg showing improvement in FVC at Wk. 52, with 120mg also slowing the decline of FVC but was not statistically significant. Company will evaluate P-III data, engage health authorities to support planned filings, & present results in the future
- Admilparant is also being studied in the fully enrolled P-III (ALOFT-PPF) trial for the treatment of pts (n=~1,057; ≥21yrs.) with progressive pulmonary fibrosis, with topline results anticipated in early 2027
Ref: Businesswire | Image: BMS | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
